Abstract
The role of pharmacogenetic (PGx) guidance in psychopharmacologic management of mental health disorders in children remains unclear for many providers. There continues to be debate in the literature, and a recent pediatric study reflected negative findings when combinatorial PGx findings were applied to clinical care. However, multiple FDA-approved medications have PGx-related dosing guidance. Among the limitations of PGx testing has been the concern that providers are highly influenced by the combinatorial results from commercial labs that drive the selection of medication and at times may cause the practitioner to deviate from evidence-based guidelines.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
